vTv Therapeutics - Class A opened lower at $21.30, compared with its previous close of $21.47. In the last trading session, the stock traded between $20.41 and $21.30. It showed a downward intraday trend.
An investment of $100 made 5 years ago in vTv Therapeutics - Class A is now worth
$ 34.20
Resulting in a loss of
$ 65.80 (65.80%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.95 (-4.42%)
Day High
$21.30
Day Low
$20.41
Day Open
$21.30
Prev Close
$21.47
Volume
8,510
1W Return
-14.19%
1M Return
-32.76%
3M Return
-37.95%
6M Return
-32.63%
1Y Return
-29.48%
Market Cap ($ Mn)
81
PE Ratio
-
PB Ratio
1.63
PEG Ratio
-
ROE
-98.44%
ROCE
-64.72%
EPS (TTM)
$-2.90
1 Week
-14.19%
1 Month
-32.76%
3 Months
-37.95%
6 Months
-32.63%
9 Months
-40.33%
vTv Therapeutics posts $11.6 million net loss in Q3 2026
Net loss widened to $11.6 million in Q3 2026 from $8.7 million in Q3 2025. Cash and cash equivalents stood at $77.2 million as of September 30, 2026. R&D expenses increased to $7.5 million driven by Phase 3 CATT1 trial costs. FDA granted Orphan Drug Designation to HPPD for sickle cell disease treatment.
7 days agovTv Therapeutics: 54% of T1D AID users face hypoglycemia burden
54% of adults with Type 1 Diabetes using automated insulin delivery experience clinically meaningful hypoglycemia-related burden. 24% of AID users report frequent Level 2 hypoglycemia events daily or almost daily. vTv Therapeutics advances cadisegliatin, an oral glucokinase activator, as an adjunctive therapy to address this unmet need.
1mo agovTv Therapeutics completes Phase 3 cadisegliatin T1D trial enrollment
vTv Therapeutics completed enrollment for its Phase 3 CATT1 study. A total of 166 patients were randomized in the trial. Cadisegliatin is an oral glucokinase activator for Type 1 Diabetes. The drug holds Breakthrough Therapy designation from the FDA.
1mo agovTv Therapeutics grants 2,500 stock options to non-executive employee
vTv Therapeutics Inc. disclosed the grant of 2,500 stock options to a non-executive employee under Nasdaq Listing Rule 5635(c)(4). The options, priced at $31.48 per share, vest over four years with a 25% cliff after one year. This equity incentive supports the company's recruitment strategy as it advances its lead candidate, cadisegliatin, through Phase 3 trials for type 1 diabetes.
2mo agovTv Therapeutics grants 23,500 stock options to employees
vTv Therapeutics Inc. granted 23,500 stock options to two non-executive employees with a weighted average exercise price of $31.95. The awards vest over four years under Nasdaq Listing Rule 5635(c)(4) as an inducement to employment.
3mo agoBTIG raises vTv Therapeutics price target to $57
BTIG analyst Kambiz Yazdi maintained a Buy rating on vTv Therapeutics and raised the price target to $57 from $49, signaling confidence in the stock's potential.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in vTv Therapeutics - Class A is now worth
$ 34.20
Resulting in a loss of
$ 65.80 (65.80%)
Note: Past profits do not guarantee future returns.
